Drug Profile
KN 043
Alternative Names: KN-043Latest Information Update: 23 Jul 2021
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antibacterials; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 23 Jul 2021 KN 043 is still in early research in Methicillin-resistant Staphylococcus aureus infections in China (Parenteral) (Alphamab pipeline, July 2021)
- 28 Aug 2020 No recent reports of development identified for research development in Methicillin-resistant-Staphylococcus-aureus-infections in China (Parenteral)
- 18 Jul 2016 Early research in Methicillin-resistant Staphylococcus aureus infections in China (Parenteral)